Research Topics
Species | John MarshallSummaryAffiliation: Georgetown University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancerJohn Marshall
Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road NW, Washington, DC 20007, USA
Future Oncol 9:271-81. 2013..Disease stabilization occurred in 14 patients. Conclusion: Afatinib 20 mg/day plus docetaxel was suboptimal and the study could not yield Phase II dose recommendations. The combination resulted in a manageable safety profile...
Poxvirus-based vaccine therapy for patients with advanced pancreatic cancerHoward L Kaufman
The Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, NY, USA
J Transl Med 5:60. 2007....
Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignanciesJohn L Marshall
Lombardi Cancer Center, Georgetown University Medical Center, Washington DC 20007, USA
Cancer Biol Ther 1:409-16. 2002..Therefore we performed a phase 1 clinical trial to determine the safety and recommended dose of prolonged infusion Bryostatin-1...- A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumorsJ Marshall
Division of Oncology Hematology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
Ann Oncol 15:1274-83. 2004.... - A phase II trial of ISIS 3521 in patients with metastatic colorectal cancerJohn L Marshall
Vincent T Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC 20007, USA
Clin Colorectal Cancer 4:268-74. 2004..ISIS 3521 demonstrated no clinical activity or target modulation in refractory metastatic CRC... - Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomasJohn L Marshall
Lombardi Cancer Center, Georgetown University Medical Center, 3800 Reservoir Rd, NW, Washington, DC 20007, USA
J Clin Oncol 23:720-31. 2005..We describe here the first trial in humans of the CEA-TRICOM vaccines (also including an enhancer agonist epitope within the CEA gene)... - Novel vaccines for the treatment of gastrointestinal cancersJohn L Marshall
Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
Oncology (Williston Park) 19:1557-65; discussion 1566, 1568 passim. 2005..Phase III studies to test these hypotheses are under way... - The role of bevacizumab as first-line therapy for colon cancerJohn Marshall
Developmental Therapeutics and GI Oncology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
Semin Oncol 32:S43-7. 2005..Additionally, the activity of bevacizumab is being evaluated for use in the second-line treatment setting for patients with CRC... - The impact of targeted therapy on the treatment of colorectal cancerJohn L Marshall
Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Washington, DC 20057, USA
Oncology (Williston Park) 19:19-24. 2005.... - Clinical implications of the mechanism of epidermal growth factor receptor inhibitorsJohn Marshall
Division of Hematology Oncology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
Cancer 107:1207-18. 2006..Although both classes of anti-EGFR agents target the same receptor, substantial distinctions regarding their mechanism significantly affect dosing requirements, toxicity profiles, and their use as combination agents... - The development of novel agents for the treatment of colorectal cancer: a critical review of current practice and some suggestions for the futureJohn L Marshall
Department of Hematology and Oncology, Georgetown University s Lombardi Comprehensive Cancer Center, Washington, DC 20057, USA
Clin Adv Hematol Oncol 5:167-72. 2007..Our current standards for drug development are increasingly problematic, and it is imperative that we develop new expectations and supporting standards in cancer drug development... - Phase I trial of irinotecan and epirubicin in advanced cancer. Preliminary reportJohn L Marshall
Lombardi Cancer Center, Washington, DC 20007, USA
Oncology (Williston Park) 16:17-9. 2002..Evidence of clinical activity has been observed. Accrual will continue until the maximum tolerated dose can be determined. Other schedules of the combination of irinotecan and epirubicin should be explored... - Integrating targeted agents into therapeutic regimens for patients with resectable colorectal cancerJohn L Marshall
Division of Hematology Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
Clin Colorectal Cancer 7:S63-6. 2008..We are increasingly managing patients with a multidisciplinary approach, a critical element in our success. Biologic therapies will continue to play an important role in the management of these patients... - Risk assessment in Stage II colorectal cancerJohn L Marshall
Division of Hematology Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Washington, DC 20007, USA
Oncology (Williston Park) 24:9-13. 2010..In this article, I will describe the current state of defining high- and low-risk disease, which is mainly through histopathologic characteristics, as well as discuss emerging approaches such as molecular markers and genomic profiling... - Biologic therapy for colon cancerAiwu Ruth He
Lombardi Cancer Center, Georgetown University Hospital, Washington, DC 20007, USA
Clin Adv Hematol Oncol 3:555-61. 2005..Additional preclinical and clinical studies will enable better usage of these biologic agents and lead to the development of new targeted therapies for the treatment of colon cancer... - Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignanciesAnatoly Dritschilo
Department of Radiation Medicine, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia 20007
Clin Cancer Res 12:1251-9. 2006..In this dose escalation study, we evaluated the safety of combined liposomal formulation of raf antisense oligonucleotide (LErafAON) and radiation therapy in patients with advanced malignancies... - Carcinoembryonic antigen-based vaccinesJohn Marshall
Department of Developmental Therapeutics, Georgetown University Medical Center, Washington, DC 20007, USA
Semin Oncol 30:30-6. 2003..1, ICAM-1, and LFA-3) has also stimulated significant T-cell increases. This review summarizes these studies and discusses the role of CEA in cancer immunotherapy... - TRICOM: enhanced vaccines as anticancer therapyBenjamin Levy
Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd NW, Washington, DC 20007, USA
Expert Rev Vaccines 3:397-402. 2004..Through stimulation of cancer-specific T-cell responses, researchers have demonstrated interesting clinical efficacy in addition to the high safety profile in clinical trials... - A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancerNaiyer A Rizvi
Developmental Therapeutics Program, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
Clin Cancer Res 10:1963-70. 2004.... - Optimum use of biologics and role of maintenance therapy in colon cancerJohn Marshall
Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 2057, USA
Semin Oncol 33:S33-5. 2006..Clinical trials involving novel agents as maintenance therapy are needed... - Differential expression of carcinoembryonic antigen (CEA) splice variants in whole blood of colon cancer patients and healthy volunteers: implication for the detection of circulating colon cancer cellsRegina Hampton
Department of Oncology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
Oncogene 21:7817-23. 2002..g. by RT-PCR). The discovery of a physiologically expressed CEA splice variant might lead to a better understanding of the biological function of CEA and its family members... - The standard of care in oncology is unacceptableJohn Marshall
Lombardi Cancer Center, Georgetown University, Washington, DC, USA
Oncology (Williston Park) 20:806. 2006 - A phase I trial of depsipeptide (FR901228) in patients with advanced cancerJohn L Marshall
Georgetown University, 3800 Reservoir Rd, NW, Washington, DC, USA
J Exp Ther Oncol 2:325-32. 2002..The MTD was defined as 13.3 mg/m2 with dose limiting toxicities being grade 3 thrombocytopenia and fatigue. Depsipeptide can be safely administered when given as a 4-hour infusion and further clinical trials are warranted... - Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapyAxel Grothey
Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Oncology (Williston Park) 21:553-64, 566; discussion 566-8, 577-8. 2007..Definitive conclusions on the sequence and duration of front-line therapy and the most effective strategy to ameliorate toxicity await results of ongoing prospective clinical trials... - Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101Antonius A Miller
Wake Forest University School of Medicine, Winston Salem, NC 27157 1082, USA
J Clin Oncol 25:3055-60. 2007..We investigated dose and pharmacokinetics of erlotinib in patients with hepatic dysfunction or renal dysfunction... - Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapyLeonard B Saltz
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 25:4793-9. 2007..We assessed the safety and efficacy of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy... - Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I studyCharles M Rudin
The University of Chicago, Chicago, Illinois, USA
Clin Cancer Res 10:7244-51. 2004..Liposomal formulation may promote better intratumoral AON delivery and inhibit degradation in vivo. We conducted the first clinical evaluation of this concept using a liposomal AON complementary to the c-raf-1 proto-oncogene (LErafAON)... - Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the questionJohn F Deeken
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia 20007, USA
Cancer 113:1502-10. 2008..Consequently, these test results are supplementary to clinical judgment, which requires assessing multiple variables that contribute to phenotype to arrive at individual dosing decisions... - Carcinoembryonic antigen as a vaccine targetDongmei Wang
National Cancer Institute, 10 Center Drive, Building 10, Room 12 N226, Bethesda, MD 20892, USA
Expert Rev Vaccines 7:987-93. 2008..In this review, we will explore just one aspect of our efforts by focusing on vaccines that target carcinoembryonic antigen... - Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancerNaiyer A Rizvi
Developmental Therapeutics Program, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
J Clin Oncol 20:3522-32. 2002..The goals of this study were to determine the safety, toxicity, and pharmacokinetics of TAC-101, a novel synthetic retinoic acid receptor-alpha (RAR-alpha) selective retinoid, in patients with advanced cancer... - Capecitabine: fulfilling the promise of oral chemotherapyJimmy J Hwang
Georgetown University Medical Center, Lombardi Cancer Center, Washington DC 20007, USA
Expert Opin Pharmacother 3:733-43. 2002.... - Bevacizumab in the treatment of colorectal cancerJohn L Marshall
Division ofHematology/Oncology, Georgetown University Medical Center, Washington, DC, USA
Clin Adv Hematol Oncol 5:8-9. 2007 - Targeted therapy for colorectal cancerJimmy Hwang
Lombardi Comprehensive Cancer Center, 3800 Reservoir Road NW, Washington, DC 20007, USA
Curr Opin Investig Drugs 7:1062-6. 2006..Data supporting the use of targeted agents in the treatment of colorectal cancer are reviewed, and the "future for potential novel agents and pathways are discussed... - Immunologic therapies for gastrointestinal cancersBenjamin Levy
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
Clin Colorectal Cancer 5:37-49. 2005..The scope is focused on the variety of approaches that have been used, citing the clinical data that have been obtained and reviewing future trials... - Costimulatory molecules as adjuvants for immunotherapyJames W Hodge
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1750, USA
Front Biosci 11:788-803. 2006..This review will focus on the current state of the use of costimulatory molecules as adjuvants for immunotherapy, and in particular, as immunomodulators for cancer vaccines... - Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trialAnthony F Shields
Department of Medicine, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
Cancer 100:531-7. 2004..The primary endpoint of the study was to determine the objective response rate, and a secondary endpoint was to measure the time to disease progression... - Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day scheduleJimmy J Hwang
Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
Oncology (Williston Park) 17:37-43. 2003.... - Stem cells in gastrointestinal cancersAiwu Ruth He
Division of Hematology/Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
Dis Markers 24:217-22. 2008 - The correlation between patient characteristics and expectations of benefit from Phase I clinical trialsKevin P Weinfurt
Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
Cancer 98:166-75. 2003..The authors examined a range of patient characteristics to determine which factors were associated with greater expectations of benefit from Phase I trials... - Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicinJimmy J Hwang
Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
Oncology (Williston Park) 17:46-51. 2003..Other toxicities were acceptable and non-dose-limiting. Accrual of patients continues, at level 3A (irinotecan at 75 mg/m2, epirubicin at 25 mg/m2)... - Clinical experiences with G17DT in gastrointestinal malignanciesAiwu R He
Vincent T Lombardi Cancer Research Center, Georgetown University Medical Center, Podium Level, Corridor B, 3800 Reservoir Road, NW Washington, DC 20007, USA
Expert Rev Anticancer Ther 6:487-92. 2006..In total, there is a clear signal of efficacy with this compound, although further testing is required in order for this efficacy to be demonstrated in a manner that will support regulatory approval... - Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trialMace L Rothenberg
Vanderbilt Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232 6307, USA
J Clin Oncol 21:2059-69. 2003..In North America, no effective therapy has been available for patients with progressive metastatic colorectal cancer after front-line treatment with irinotecan, bolus fluorouracil (FU), and leucovorin (IFL)... - Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitorJohn L Marshall
Georgetown University Medical Center-Lombardi Cancer Center, Washington, DC 20007, USA
Invest New Drugs 23:31-7. 2005..Further study is necessary to determine the clinical efficacy of this novel new chemotherapeutic agent... - Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancersAndrew L Pecora
Cancer Center at Hackensack University Medical Center, Hackensack, NJ 07601, USA
J Clin Oncol 20:2251-66. 2002..This phase I study was designed to define the maximum-tolerated dose (MTD) and safety of single and multiple intravenous doses of PV701 as a single agent in patients with cancer...
Research Grants
- CEA BASED VACCINE THERAPY IN PATIENTS WITH ADVANCED CAJohn Marshall; Fiscal Year: 2005..So far, the applicant's experience with the first generation CEA-based vaccines has generated a great deal of excitement, and yet he anticipates even more from the newer vaccine constructs. ..